Shares of Natera Inc (NASDAQ:NTRA) have earned a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $14.33.
A number of research firms have issued reports on NTRA. BidaskClub raised shares of Natera from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th. Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Cowen reissued a “buy” rating and issued a $12.00 price objective on shares of Natera in a report on Thursday, December 21st. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 price target on shares of Natera in a report on Tuesday, November 14th.
Natera (NASDAQ NTRA) traded down $0.01 during midday trading on Friday, reaching $9.24. 72,000 shares of the company’s stock were exchanged, compared to its average volume of 116,589. The company has a quick ratio of 1.75, a current ratio of 1.85 and a debt-to-equity ratio of 2.43. The company has a market cap of $497.36, a P/E ratio of -3.77 and a beta of 2.18. Natera has a 52-week low of $7.35 and a 52-week high of $14.76.
Several institutional investors have recently modified their holdings of the company. MetLife Investment Advisors LLC bought a new stake in shares of Natera during the 4th quarter worth approximately $124,000. Macquarie Group Ltd. increased its position in Natera by 11.8% during the 4th quarter. Macquarie Group Ltd. now owns 1,494,152 shares of the medical research company’s stock worth $13,432,000 after purchasing an additional 157,159 shares in the last quarter. Deutsche Bank AG increased its position in Natera by 75.0% during the 4th quarter. Deutsche Bank AG now owns 81,890 shares of the medical research company’s stock worth $735,000 after purchasing an additional 35,108 shares in the last quarter. Jefferies Group LLC acquired a new position in Natera during the 4th quarter worth approximately $130,000. Finally, Geode Capital Management LLC increased its position in Natera by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 352,850 shares of the medical research company’s stock worth $3,172,000 after purchasing an additional 13,708 shares in the last quarter. 66.01% of the stock is owned by institutional investors.
Natera Company Profile
Natera, Inc is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother’s blood and a blood sample from the alleged father(s).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.